Adherex Technologies (FENC) to Release Quarterly Earnings on Tuesday

Adherex Technologies (NASDAQ:FENC) is anticipated to post its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect the company to announce earnings of $0.02 per share and revenue of $16.2060 million for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 8:30 AM ET.

Adherex Technologies (NASDAQ:FENC) last posted its quarterly earnings data on Thursday, May 14th. The company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.02) by $0.03. Adherex Technologies had a negative net margin of 17.12% and a negative return on equity of 43.87%. The business had revenue of $15.11 million during the quarter, compared to analyst estimates of $13.90 million. On average, analysts expect Adherex Technologies to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Adherex Technologies Stock Down 0.1%

Shares of FENC opened at $11.57 on Monday. Adherex Technologies has a fifty-two week low of $5.65 and a fifty-two week high of $11.66. The firm’s 50 day moving average price is $10.00 and its 200 day moving average price is $8.48. The company has a market cap of $405.64 million, a P/E ratio of -39.90 and a beta of 1.09.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on FENC shares. Wall Street Zen upgraded shares of Adherex Technologies from a “hold” rating to a “strong-buy” rating in a research note on Saturday, May 16th. Wedbush reiterated an “outperform” rating and issued a $13.00 price objective on shares of Adherex Technologies in a research note on Thursday, April 16th. HC Wainwright lifted their target price on Adherex Technologies from $13.00 to $16.00 and gave the company a “buy” rating in a report on Friday, May 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Adherex Technologies in a research note on Friday, July 17th. Finally, Zacks Research upgraded Adherex Technologies from a “strong sell” rating to a “hold” rating in a report on Monday, May 25th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Adherex Technologies presently has an average rating of “Moderate Buy” and a consensus target price of $15.40.

Hedge Funds Weigh In On Adherex Technologies

An institutional investor recently bought a new stake in Adherex Technologies stock. AQR Capital Management LLC bought a new stake in Adherex Technologies Inc. (NASDAQ:FENC) in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 10,897 shares of the company’s stock, valued at approximately $66,000. 55.51% of the stock is currently owned by institutional investors.

About Adherex Technologies

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014. Fennec Pharmaceuticals Inc was founded in 1996 and is based in Research Triangle Park, North Carolina.